ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

REGN Regeneron Pharmaceuticals Inc

937.61
0.00 (0.00%)
Pre Market
Last Updated: 09:38:46
Delayed by 15 minutes
Share Name Share Symbol Market Type
Regeneron Pharmaceuticals Inc NASDAQ:REGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 937.61 578.26 1,104.00 124 09:38:46

Statement of Changes in Beneficial Ownership (4)

23/06/2017 9:11pm

Edgar (US Regulatory)


FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Aberman Michael S
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS INC [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP Strategy Investor Relation
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

6/21/2017
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/21/2017     M (1)    4500   A $30.63   9193   D    
Common Stock   6/21/2017     F (1)    270   D $510.02   8923   D    
Common Stock   6/21/2017     F (1)    1961   D $510.02   6962   D    
Common Stock   6/22/2017     S (1)    395   D $525.21   (2) 6567   D    
Common Stock   6/22/2017     S (1)    100   D $526.02   6467   D    
Common Stock   6/22/2017     S (1)    100   D $529.61   6367   D    
Common Stock   6/22/2017     S (1)    100   D $530.66   6267   D    
Common Stock   6/22/2017     S (1)    274   D $531.51   (3) 5993   D    
Common Stock   6/22/2017     S (1)    200   D $532.27   (4) 5793   D    
Common Stock   6/22/2017     S (1)    200   D $533.48   (5) 5593   D    
Common Stock   6/22/2017     S (1)    200   D $534.51   (6) 5393   D    
Common Stock   6/22/2017     S (1)    400   D $536.52   (7) 4993   D    
Common Stock   6/22/2017     S (1)    100   D $537.5   4893   D    
Common Stock   6/22/2017     S (1)    100   D $538.3   4793   D    
Common Stock   6/22/2017     S (1)    100   D $541.0   4693   D    
Common Stock                  11805   I   by GRAT  
Common Stock                  448   I   By 401(k) Plan  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy)   $30.63   6/21/2017     M   (1)       4500      (8) 12/14/2020   Common Stock   4500   $0.0   3000   D    

Explanation of Responses:
(1)  Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2)  Represents volume-weighted average price of sales of 395 shares of Company stock on June 22, 2017 at prices ranging from $525.00 to $525.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
(3)  Represents volume-weighted average price of sales of 274 shares of Company stock on June 22, 2017 at prices ranging from $531.05 to $531.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
(4)  Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $532.18 to $532.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
(5)  Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $533.17 to $533.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
(6)  Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $534.16 to $534.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
(7)  Represents volume-weighted average price of sales of 400 shares of Company stock on June 22, 2017 at prices ranging from $536.15 to $536.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
(8)  The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Aberman Michael S
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


SVP Strategy Investor Relation

Signatures
/s/**Michael S. Aberman 6/23/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year Regeneron Pharmaceuticals Chart

1 Year Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock